Pharmacokinetics and Pharmacodynamics of a Novel Acetylcholinesterase Inhibitor, DMNG-3

Acta Neurobiologiae Experimentalis - Poland
doi 10.21307/ane-2017-011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Exeley, Inc.

Related search

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination With Meropenem

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986142, a Novel Reversible BTK Inhibitor, in Healthy Participants

European Journal of Clinical Pharmacology
MedicinePharmacology
2017English

Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics

Journal of Clinical Pharmacology
Pharmacology
2010English

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin

Pharmaceutics
Pharmaceutical Science
2020English

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Clinical Cancer Research
Cancer ResearchOncology
2014English

Pharmacokinetics and Pharmacodynamics of Tecarfarin, a Novel Vitamin K Antagonist Oral Anticoagulant

Thrombosis and Haemostasis
Hematology
2017English

Pharmacokinetics and Pharmacodynamics of Suxamethonium

Anaesthesia and Intensive Care
Critical CareAnesthesiologyPain MedicineIntensive Care Medicine
1997English

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin

Clinical Pharmacokinetics
Pharmacology
2015English

Preclinically Pharmacokinetics and Pharmacodynamics Re-Evaluation of Sodium Glycididazole—A Novel Hypoxia Radiosensitizer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy